Guideline Profile : Juvenile Idiopathic Arthritis

You are here : Home > Formulary Search > Guideline Profile : Juvenile Idiopathic Arthritis

Documentation

Guidelines (Local)

High-cost drugs for adults with juvenile idiopathic arthritis treatment pathway - SERMOG-05 - updated January 2026

Information

Biologics in adults with Juvenile Idiopathic Arthritis - BSPAR Position statement

Drugs

Below are listed all drugs that are used to treat Juvenile Idiopathic Arthritis.

Committee Recommendations (0)

No records returned.

Guideline Profile

Indication :

Juvenile Idiopathic Arthritis

Keywords :

JIA, NICE, NHS England, pain, arthritis, SERMOG, South East Region Medicines Optimisation Group, polyarticular, polyarticular-onset, polyarticular-course, extended oligoarticular JIA

Brand Names Include :

Ilaris, Enbrel, Benepali, Erelzi, Orencia, Humira, RoActemra, Amgevita, Hyrimoz, Idacio, Imraldi, Yuflyma, Erelzi, Tyenne, tofacitinib, adalimumab, abatacept, tocilizumab, etanercept, Xelijanz,

Important Information :

Responsible commissioner is NHS England until the patient moves into the care of the adult service, at this point the responsible commissioner will be the ICB.

Latest Additions Date From :

Latest Additions Date To :

Supporting Documents :